List of Tracleer drug patents

Tracleer is owned by Actelion.

Tracleer contains Bosentan.

Tracleer has a total of 2 drug patents out of which 0 drug patents have expired.

Tracleer was authorised for market use on 05 September, 2017.

Tracleer is available in tablet, for suspension;oral dosage forms.

The generics of Tracleer are possible to be released after 28 December, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8309126 ACTELION Dispersible bosentan tablet
May, 2026

(3 years from now)

US7959945 ACTELION Dispersible bosentan tablet
Dec, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 5, 2024

Drugs and Companies using BOSENTAN ingredient

Market Authorisation Date: 05 September, 2017

Treatment: NA

Dosage: TABLET, FOR SUSPENSION;ORAL

How can I launch a generic of TRACLEER before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in